Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Melanoma 9Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Colorectal Neoplasms 5Lymphoma 4Liver Neoplasms 4Lung Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma 2Locally Advanced Rectal Cancer 2Hematologic Diseases 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor, Adult 1

Interventions

Imatinib Mesylate 41Sunitinib 17nilotinib 12regorafenib 10ripretinib 6avapritinib 6Leucovorin 3Ipilimumab 3Gemcitabine 3Dasatinib 3CTLA-4 Antigen 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2Paclitaxel 2Oxaliplatin 2Midazolam 2Irinotecan 2Fluorouracil 2Floxuridine 2Erlotinib Hydrochloride 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2Biopsy, Fine-Needle 2Bevacizumab 2vatalanib 1umbralisib 1trametinib 1tinostamustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Stromal Tumors × spartalizumab × Clear all
NCT03609424 2023-01-03

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

Asan Medical Center

Phase 1/2 Completed
39 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡